10
18
2021
On October 12, the sub-forum of International Biopharm Industry Week Shanghai 2012 - Zhangjiang Life Science International Innovation Summit hosted by Shanghai Medicilon Inc. (Medicilon), Internationalization Trend of Chinese Pharmaceutical Companies and AI R&D Innovation Forum and Zhangjiang AI New Drug R&D Alliance Establishment Conference was successfully held in Shanghai.
09
22
2021
In the field of IL-23 monoclonal antibody drug research and development, Medicilon's Pharmacodynamics Department has been deeply involved for many years, has an excellent evaluation ability of animal efficacy evaluation models, and strictly complies with the GLP specifications of NMPA, OECD and FDA.
08
06
2021
As a collaborative partner of Kumquat, Shanghai Medicilon Inc. (Medicilon) congratulates the Kumquat Biosciences on the new progress of small molecule immuno-oncology (IO) platform.
08
06
2021
Shanghai Medicilon Inc. (Medicilon) provides a range of preclinical services from drug targets to IND filing in the development of RG001 tablets to enter the clinical trial phase, including drug discovery, pharmaceutical research, and pre-clinical research (drug efficacy and safety evaluations).
08
06
2021
Shanghai Medicilon Inc. (Medicilon) provided a full set of preclinical research services including pharmacokinetics and safety evaluation in the development of LDS tablets. Medicilon successfully assisted China’s first targeted transient receptor LDS, a small molecule inhibitor of potential channels, to enter the clinical trial stage. targeting transient receptor potential channels.
